AUROBINDO PHARMA LTD. - 524804 - Completion Of US FDA Inspection At Synthetic Peptide API Facility Of Auro Peptides Ltd., A Subsidiary Of The Company
Intimation of completion of USFDA Inspection at synthetic peptide API facility of Auro Peptides Limited, a subsidiary of the Company Aurobindo Pharma Q3 Review - Business Outlook Stable; Outcome Of U.S. FDA Inspection Remains Key: DRChoksey
Strong growth in specialty and injectable in the U.S. drives the top-line AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificates
Accumulate Aurobindo Pharma; target of Rs 1120: Prabhudas Lilladher
Prabhudas Lilladher recommended accumulate rating on Aurobindo Pharma with a target price of Rs 1120 in its research report dated February 13, 2024.
Aurobindo Pharma Q3 Results Review - Niche Products Led Earnings Growth: Motilal Oswal
Product mix benefit and better operating leverage led improved margins.
Aurobindo Pharma Expects Biosimilars To See Significant Opportunity In FY26
The Hyderabad-based bulk and generic drug maker's growth during the third quarter was mainly driven by volume gains, stable demand, and new product launches. AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate. AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on receipt of US FA Approval for Deflazacort Tablets AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Earnings Call held on 12th February 2024 on Q3FY24 Unaudited Financial Results Q3FY24 Quarterly Result Announced for Aurobindo Pharma Ltd.
Pharmaceuticals company Aurobindo Pharma announced Q3FY24 results: Revenue from Operations increased by 14.7% YoY to Rs 7,352 crore with growth seen across multiple businesses. US formulations (excluding Puerto Rico) revenue increased by 28.9% YoY to Rs 3,756 crore (USD 451 million). Europe formulation revenue increased by 1.6% YoY to Rs 1,728 crore (EUR 193 million). Growth Markets revenue increased by 25.6% YoY to Rs 627 crore (USD 75 million). ARV revenue decreased by 28.6% YoY to Rs 179 crore (USD 22 million). API revenue grew by 7.1% YoY to Rs 1,022 crore (USD 123 million). EBITDA before Forex and Other income stood at Rs 1,601 crore; EBITDA margin of 21.8%. Research & Development (R&D;) spend stood at Rs 398 crore, 5.4% of revenues (vs. Q2 FY24: 4.2%). Received final approval for 16 ANDAs including 7 specialty & injectable products from the USFDA. Net Profit after Share of Profit/Loss of JV and minority interest at Rs 936 crore, vs. Rs 491 crore in Q3FY23. Basic & Diluted EPS grew by 91.4% YoY to Rs 16.04 per share. Board has approved interim dividend @ 150% i.e. Rs 1.5 per equity share of Rs 1/- for FY24. Commenting on the Company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “We are very pleased with the considerable progress we have made in our operations, and the cost efficiencies we have achieved, this quarter’s highest ever sales and EBITDA reflect the same. With our continued focus on developing a strong pipeline and driving the commercialization of our key projects, we are confident of our growth trajectory in the months ahead.” Result PDF